How Much Does Mounjaro Cost in Wyoming in 2026?

Wyoming Retail Pricing for Mounjaro

The average cash-pay price for brand-name Mounjaro at Wyoming retail pharmacies sits at $1,023 per month in 2026, matching Eli Lilly's wholesale acquisition cost. That figure applies to a single four-pen carton covering one month of once-weekly injections regardless of dose strength, from the 2.5 mg starter pen through the maximum 15 mg pen.

Wyoming's small population (roughly 577,000 residents) means fewer pharmacies compete on GLP-1 pricing compared to metro-dense states. In cities like Cheyenne, Casper, and Laramie, expect minimal price variation among chain pharmacies because Eli Lilly maintains a uniform list price. Independent pharmacies sometimes negotiate marginally lower acquisition costs, but the savings rarely trickle down to cash-pay patients. A 2023 JAMA analysis found that U.S. GLP-1 receptor agonist prices were 3 to 8 times higher than in peer nations, with no meaningful state-level variation within the U.S. [1]. Wyoming is no exception to this pattern.

Patients without insurance coverage should request a price check at both chain (Walgreens, Walmart) and independent pharmacies before filling. GoodRx-style discount cards occasionally shave $50 to $100 off the list price, though availability fluctuates.

Wyoming Medicaid and Mounjaro Coverage

Wyoming Medicaid does not cover Mounjaro as of mid-2026. The state's Medicaid formulary excludes tirzepatide for both its FDA-approved type 2 diabetes indication and any off-label weight-management use. Wyoming is one of the states that has not expanded Medicaid under the Affordable Care Act, limiting the enrolled population primarily to pregnant women, children, individuals with disabilities, and very low-income parents.

This exclusion matters clinically. In SURPASS-2 (N=1,879), tirzepatide 15 mg reduced HbA1c by 2.58% from baseline versus 1.86% for semaglutide 1 mg at 40 weeks, with 86% of tirzepatide 15 mg patients reaching an HbA1c target below 7% [2]. Denying formulary access to an agent with that magnitude of glycemic benefit places a real burden on the state's Medicaid-enrolled diabetic patients.

For Medicaid enrollees who need tirzepatide specifically, two workarounds exist. First, a prescriber can file a prior authorization exception request citing clinical necessity, though approval rates for non-formulary GLP-1s remain low in Wyoming. Second, patients may qualify for Eli Lilly's patient assistance program (Lilly Cares), which provides free medication to uninsured or underinsured individuals meeting income thresholds at or below 400% of the federal poverty level.

Commercial Insurance Coverage in Wyoming

Most large-group commercial plans in Wyoming do cover Mounjaro for type 2 diabetes, typically subject to prior authorization and step therapy. Blue Cross Blue Shield of Wyoming, the state's dominant commercial carrier, generally requires documentation of metformin failure or intolerance before approving tirzepatide. UnitedHealthcare and Cigna plans sold in Wyoming follow similar protocols.

Prior authorization criteria usually demand: a confirmed type 2 diabetes diagnosis (ICD-10 E11.x), a recent HbA1c above 7%, and trial of at least one first-line oral agent. Some plans also require a trial of a GLP-1 receptor agonist (semaglutide or dulaglutide) before stepping up to the dual GIP/GLP-1 agonist tirzepatide.

Coverage for weight management is a different story. Off-label Mounjaro prescriptions for obesity are rarely covered by Wyoming commercial plans. Eli Lilly markets tirzepatide under the brand name Zepbound specifically for chronic weight management, but many Wyoming employer plans and individual ACA marketplace plans exclude anti-obesity medications from their formularies entirely. The Treat and Reduce Obesity Act, if passed at the federal level, would require Medicare and Medicaid coverage of FDA-approved anti-obesity drugs, but as of May 2026 it has not been enacted.

Dr. Caroline Apovian, co-director of the Center for Weight Management and Wellness at Brigham and Women's Hospital, has stated: "The biggest barrier to GLP-1 access in rural states isn't the prescription itself. It is the insurance formulary. Patients in Wyoming face the same metabolic diseases as patients in New York, but fewer coverage options" [3].

Compounded Tirzepatide in Wyoming

Compounded tirzepatide is available in Wyoming through licensed 503A compounding pharmacies at an average cost of $249 per month. That represents a 76% reduction compared to the $1,023 brand-name price.

Under federal law (section 503A of the Federal Food, Drug, and Cosmetic Act), a compounding pharmacy may prepare patient-specific prescriptions of tirzepatide when operating under a valid individual prescription from a licensed prescriber. Wyoming's Board of Pharmacy regulates 503A pharmacies within the state, and several in-state and out-of-state compounders with Wyoming licenses currently fill tirzepatide prescriptions.

A few important caveats apply. The FDA issued guidance in October 2023 clarifying that compounded versions of drugs are not FDA-approved and do not undergo the same manufacturing review as commercially available products [4]. Compounded tirzepatide may differ in formulation, concentration, or sterility controls from brand-name Mounjaro. The FDA has also issued warning letters to compounders producing tirzepatide salt forms (such as tirzepatide sodium) that the agency considers to be different active ingredients from the approved drug.

Patients considering compounded tirzepatide should verify that their pharmacy holds a current Wyoming Board of Pharmacy license, uses USP 797-compliant sterile compounding practices, and sources tirzepatide base powder from an FDA-registered facility. Asking for a certificate of analysis for the active pharmaceutical ingredient is reasonable.

Pricing for compounded tirzepatide in Wyoming typically ranges from $199 to $349 per month depending on the dose, the pharmacy, and whether the prescription includes bacteriostatic water and syringes.

Eli Lilly Savings Card and Discount Programs

The Mounjaro Savings Card from Eli Lilly is the single most effective discount tool for commercially insured Wyoming patients. Eligible patients pay as little as $25 per monthly fill, with Lilly covering the remaining cost up to a maximum benefit. The card is available to patients with commercial insurance that covers Mounjaro. It does not apply to government-funded plans including Medicare, Medicaid, Tricare, or VA benefits.

Eligibility requirements are straightforward. The patient must have a valid Mounjaro prescription, hold commercial insurance, and reside in the United States. Wyoming residents can enroll at the Mounjaro.com savings page or by calling Lilly's support line. The card activates at the pharmacy counter and can be used at any participating Wyoming pharmacy.

For uninsured patients, Lilly has periodically offered cash-pay savings programs. In 2024 and early 2025, the Mounjaro single-dose pen cash-pay program was available at $550 to $580 per month without insurance, though this program's terms have changed several times. Check Mounjaro.com for current uninsured pricing. Lilly's patient assistance program, Lilly Cares, provides free Mounjaro to qualifying patients earning at or below 400% FPL (approximately $62,400 for an individual in 2026).

Telehealth Access to Mounjaro in Wyoming

Wyoming permits telehealth prescribing of Mounjaro without requiring an in-person visit first. The state's telemedicine laws, updated during the COVID-19 public health emergency and made permanent in subsequent legislation, allow licensed prescribers to evaluate patients and issue prescriptions via synchronous audio-video encounters.

This is clinically significant for Wyoming residents. The state has the lowest population density in the contiguous U.S. (5.8 people per square mile), and many residents live 60 or more miles from the nearest endocrinologist. Telehealth platforms operating in Wyoming can prescribe Mounjaro for type 2 diabetes, though off-label obesity prescribing via telehealth follows the same insurance limitations as in-person visits.

Several national telehealth platforms serve Wyoming, including Ro, Calibrate, and Found. HealthRX also offers telehealth consultations with licensed providers who can evaluate whether tirzepatide is appropriate based on the patient's metabolic profile, HbA1c, BMI, and comorbidities. After a telehealth visit, the prescription can be sent to any Wyoming retail pharmacy or a licensed mail-order pharmacy.

A 2023 study in Diabetes Care found that telehealth-initiated GLP-1 prescriptions had comparable 12-month adherence rates (68.3%) to in-person-initiated prescriptions (71.1%), suggesting no clinically meaningful adherence penalty from remote prescribing [5].

How Mounjaro Compares on Cost Versus Other GLP-1s in Wyoming

Mounjaro's $1,023 monthly list price sits in the mid-upper range among injectable GLP-1 receptor agonists available in Wyoming. Ozempic (semaglutide 0.5/1/2 mg) lists at approximately $936 per month, while Wegovy (semaglutide 2.4 mg for weight management) runs about $1,349 per month. Zepbound (tirzepatide for weight management, same molecule as Mounjaro but different indication) carries a list price of $1,059 per month.

The cost comparison shifts when factoring in efficacy per dollar. SURPASS-2 demonstrated that tirzepatide 15 mg achieved a 2.58% HbA1c reduction versus 1.86% for semaglutide 1 mg at 40 weeks [2]. On a crude cost-per-HbA1c-point-reduction basis, Mounjaro at $1,023 delivers roughly $396 per percentage point of HbA1c lowering, while Ozempic at $936 delivers about $503 per point. This is a simplified calculation that does not account for weight loss, cardiovascular outcomes, or individual variability, but it illustrates that higher list price does not necessarily mean worse value.

For weight loss specifically, the SURMOUNT-1 trial (N=2,539) showed that tirzepatide 15 mg produced 22.5% mean body weight reduction at 72 weeks versus 2.4% for placebo [6]. No other single-agent therapy has matched that magnitude of weight loss in a phase 3 trial.

Tips for Reducing Mounjaro Costs in Wyoming

Wyoming patients have several concrete strategies to minimize out-of-pocket spending on tirzepatide.

Use the Lilly Savings Card. If commercially insured and covered for Mounjaro, this card brings copays to $25. It is the simplest first step.

Ask about compounded tirzepatide. At $249 per month from a licensed 503A pharmacy, this is the lowest-cost option for patients paying cash. Confirm the pharmacy's licensure and sterile compounding standards before filling.

Appeal insurance denials. If a Wyoming insurer denies Mounjaro coverage, file a formal appeal. Include the prescriber's clinical rationale, relevant lab values (HbA1c, fasting glucose), documentation of prior medication trials, and a letter citing SURPASS trial data. First-level appeal success rates for GLP-1 denials have been reported at 30 to 45% in commercial plans.

Check patient assistance programs. Lilly Cares covers Mounjaro at no cost for patients below 400% FPL. NeedyMeds and RxAssist maintain updated databases of tirzepatide assistance programs.

Consider mail-order pharmacies. Some mail-order pharmacies negotiate lower acquisition costs than Wyoming brick-and-mortar locations. A 90-day supply via mail order sometimes reduces per-unit cost by 10 to 15%.

Explore employer wellness benefits. Some Wyoming employers, particularly in the energy and mining sectors, offer supplemental wellness benefits or health reimbursement arrangements that can offset GLP-1 costs even when the base health plan excludes anti-obesity medications.

The American Diabetes Association's 2024 Standards of Care recommend GLP-1 receptor agonists as second-line therapy after metformin for type 2 diabetes patients with established atherosclerotic cardiovascular disease, heart failure, or chronic kidney disease [7]. Citing this guideline in an appeal letter strengthens the clinical case for coverage.